Author： Dean Emma J Ranson Malcolm Blackhall Fiona Dive Caroline
Publisher： Informa Healthcare
ISSN： 1472-8222
Source： Expert Opinion on Therapeutic Targets, Vol.11, Iss.11, 2007-11, pp. : 1459-1471
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Dysregulation of apoptosis has been shown to contribute to many diseases, including cancer formation, development and resistance, as well as neurodegenerative and autoimmune disorders. One mechanism through which tumour cells are believed to acquire resistance to apoptosis is by overexpression of X-linked inhibitor of apoptosis protein (XIAP), which belongs to a family of inhibitor of apoptosis proteins. When XIAP is overexpressed, cancer cells are rendered resistant to apoptosis, both intrinsically and in response to chemotherapy and radiotherapy. Significant progress has been made in targeting XIAP therapeutically, both directly and indirectly through the modulation of other molecules involved in the apoptotic pathway. This review introduces XIAP from its molecular origins, discusses its modulation and potential as a novel drug target, and considers future therapeutic perspectives.
Related content
The Journal of International Medical Research, Vol. 39, Iss. 5, 2011-09 ,pp. :
Access to resources
Recommend
&bgr;-Secretase as a Therapeutic Target for Inhibitor Drugs
Current Medicinal Chemistry, Vol. 9, Iss. 11, 2002-06 ,pp. :
Neuronal apoptosis as a therapeutic target in neurodegenerative disease
By Larner A.
Expert Opinion on Therapeutic Patents, Vol. 10, Iss. 10, 2000-10 ,pp. :